Blockade of the PD-L1/PD-1 axis not only promotes activation of tumor-infiltrating CD8+ T cells that leads to tumor control, but also improves the number and functionality of SCL CD8+ T cells within tumors (Castiglioni et al., 2023; Peng et al., 2020; Siddiqui et al., 2019). This evidence concerns the gene CD8A and neoplasm.